Drugs /

rabbit anti-thymocyte globulin

Back to Drugs List

Overview

Generic Name(s):
anti-thymocyte globulin rabbit, grafalon, ratg, rabbit atg, rabbit antithymocyte globulin, and thymoglobulin

Clinical Trials

View Clinical Trials for rabbit anti-thymocyte globulin

Rabbit anti-thymocyte globulin has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating rabbit anti-thymocyte globulin, 1 is phase 2 (1 open).

BCR-ABL1 Fusion, CBFA2T3-GLIS2 Fusion, and Complex karyotype are the most frequent biomarker inclusion criteria for rabbit anti-thymocyte globulin clinical trials.

Acute biphenotypic leukemia, acute erythroid leukemia, and acute lymphoblastic leukemia are the most common diseases being investigated in rabbit anti-thymocyte globulin clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Rabbit Anti-Thymocyte Globulin
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating rabbit anti-thymocyte globulin and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
thymoglobulin, ratg, rabbit atg, rabbit antithymocyte globulin, grafalon, anti-thymocyte globulin rabbit
Drug Target(s) [2]:
THY1
NCIT ID [1]:
C153136

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.